Two trials with nineteen control sera were used to assess external immunoserology quality control between member laboratories. In this assessment, eight immunoserology items were included. Those were antistreptolysin O (ASO), C-reactive protein
(CRP),
Rheumatoid factor (RF), Serologic tests for syphilis (STS), hepatitis B surface antigen (HBs Ag), hepatitis B surface antibody (Anti-HBs) and anti-HCV was added as a new test item. The annual report on external quality assessment in
immunoserology
was
summarized as follows.
The response rates and results of previously tested seven immunoserology items showed no marked difference as compared to previous years report.
The response rates for anti-HCV test was relatively low, 39.2% (S-93-10) and 46.7% (S-93-29)respectively. The result of Anti-HCV trial S-93-29serum showed 89% agreement between member laboratories in EIA. But, the result of S-93-10 serum showed
marked
discordant interlaboratory data (58% agreement) in EIA method. It is assumed that these disagreements in the EIA results of S-93-10 serum may be the test results of anti-HCV are affected by the reagents provided by different companies. To confirm
these
result, the Western blot(recombinant immunoblot assay, RIBA) was performed and it turned out to be indeterminate.
|